Cargando…

Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat

Gaucher disease (GD) causes the accumulation of glucocerebrosides in various organs, resulting in hepatosplenomegaly, anemia, decreased platelet counts, and bone disorders. Glucosylsphingosine accumulates in the brain and causes central nervous system (CNS) disorders. GD can be classified into types...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harai, Nozomi, Ichijo, Masashi, Uchinuma, Hiroyuki, Hanihara, Mitsuto, Kawaguchi, Yoshihiko, Ichikawa, Daisuke, Tsuchiya, Kyoichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641180/ https://www.ncbi.nlm.nih.gov/pubmed/36889706 http://dx.doi.org/10.2169/internalmedicine.1425-22

Ejemplares similares

Profile of eliglustat tartrate in the management of Gaucher disease
por: Sechi, Annalisa, et al.
Publicado: (2016)

Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin
por: Uchinuma, Hiroyuki, et al.
Publicado: (2020)

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
Publicado: (2016)

A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
por: Komada, Naoto, et al.
Publicado: (2021)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
por: Bennett, Lunawati L, et al.
Publicado: (2015)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease [Corrigendum]
Publicado: (2015)

Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1
por: Vu, Lucie, et al.
Publicado: (2020)

Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease
por: Kleytman, Nathaniel, et al.
Publicado: (2021)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States
por: Nalysnyk, Luba, et al.
Publicado: (2018)

A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat
por: Abrams, Ruth, et al.
Publicado: (2020)

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
por: Kamath, Ravi S., et al.
Publicado: (2014)

The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review
por: Nabizadeh, Azita, et al.
Publicado: (2018)

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3
por: Lee, Ni-Chung, et al.
Publicado: (2022)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Ibrahim, Jennifer, et al.
Publicado: (2016)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials
por: Lukina, Elena, et al.
Publicado: (2020)

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
por: Lukina, Elena, et al.
Publicado: (2018)

Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
por: Kim, Yoo-Mi, et al.
Publicado: (2017)

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1
por: Peterschmitt, M. Judith, et al.
Publicado: (2019)

Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat
por: Sidhu, Karamjot, et al.
Publicado: (2020)

Suicidal attempt with eliglustat overdose
por: Nadler, Johannes, et al.
Publicado: (2022)

Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial
por: Mistry, Pramod K., et al.
Publicado: (2017)

P1541: PRELIMINARY RESULTS OF TWO YEARS FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS TREATED WITH ELIGLUSTAT IN TRAZELGA PROJECT.
por: Serrano-Gonzalo, I., et al.
Publicado: (2022)

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
por: Mistry, Pramod K., et al.
Publicado: (2021)

Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats
por: Wang, Qiong, et al.
Publicado: (2019)

Acute Kidney Injury with Hemolysis after Glycerin Enema-induced Rectal Injury in a Patient with Type 2 Diabetes
por: Hayashida, Ryosuke, et al.
Publicado: (2020)

Follicle-stimulating Hormone-secreting Pituitary Adenoma Accompanied by Painful Thyroiditis
por: Ichijo, Masashi, et al.
Publicado: (2019)

NI-18 A Quantitative Analysis of Intraoperative 3T-Diffusion Tensor Imaging parameters for Functional Prediction with Motor Eloquent Glioma Patients
por: Kawataki, Tomoyuki, et al.
Publicado: (2021)

Melanocortin-4 receptor in macrophages attenuated angiotensin II-induced abdominal aortic aneurysm in mice
por: Mori, Kentaro, et al.
Publicado: (2023)

BT-7 Long-term outcome and late adverse effects of intracranial primary germ cell tumor
por: Hanihara, Mitsuto, et al.
Publicado: (2021)

Attitudes of Individuals with Gaucher Disease toward Substrate Reduction Therapies
por: Wagner, Victoria F., et al.
Publicado: (2017)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Total Synthesis of Eliglustat via Diastereoselective Amination of Chiral para-Methoxycinnamyl Benzyl Ether
por: Kong, Younggyu, et al.
Publicado: (2022)

Liver involvement in patients with Gaucher disease types I and III
por: Starosta, Rodrigo Tzovenos, et al.
Publicado: (2020)

Intracranial Pial Arteriovenous Fistula Caused by Dural Tenting: Case Report
por: NISHIYAMA, Yoshihisa, et al.
Publicado: (2014)

CO-01 Prediction of pathological and radiological nature of glioma by mass spectrometry combined with machine learning
por: Kawataki, Tomoyuki, et al.
Publicado: (2020)

Prediction of Pathological and Radiological Nature of Glioma by Mass Spectrometry Combined With Machine Learning
por: Suzuki, Keiko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nsmakjslticn9a6u0k2jip5hpd